Verastem says it is eyeing early 2018 for a new drug application to the FDA for its new but troubled oncology asset duvelisib.
Daiichi Sankyo has teamed up with Glycotope to develop an antibody-drug conjugate with potential in ovarian, lung and breast cancers.
The deal sees AstraZeneca join Novartis among Mereo’s shareholders and further its efforts to offload deprioritized drugs.
The investment group told the world of its desire to buy the ADHD specialist after twice being rebuffed.
Germany’s Evotec has penned another deal amid a stream of R&D pacts over the past year, this time with PARP player Tesaro.
The deal, which includes $750 million in milestones, is Incyte’s second attempt to land a PD-1 drug to pair with its pipeline of oncology prospects.…
Despite 15 years of hurt for biopharma R&D in Alzheimer’s, AbbVie and Alector are still throwing in together to work on the disease.
The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.
Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.
The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.